Company: IMRX
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001790340-25-000053
Chunk: 15

Company: Immuneering Corp
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 15
---
 September 2004 until January 2014, she served as the Senior Vice President, General Counsel and Secretary of Millennium Pharmaceuticals, Inc., a wholly owned oncology-focused subsidiary of Takeda Pharmaceutical Company Limited since 2008, and was the founding Chief Executive Officer and a member of the board of directors of Hydra Biosciences. Since December 2021 Ms. Keating has served on and currently chairs the board of directors of a clinical-stage biopharmaceutical company, PepGen Inc. (Nasdaq: PEPG), where she is a member of the Audit, Compensation and Nominating and Corporate Governance committees. From November 2021 until the company was acquired by Merck in January 2023, she served on the board of directors of Imago BioSciences (Nasdaq: IMGO), and from 2005 until March 2022 she served on the board of directors of MassBIO, a non-profit organization. Ms. Keating earned her A.B. in economics from the University of California, Berkeley and her J.D. from the University of California, Hastings College of the Law. We believe that Ms. Keating is qualified to serve on our Board of Directors due to her extensive leadership skills and experience in the biotechnology industry.

Class III Directors Whose Terms Expire at the 2027 Annual Meeting of Stockholders

| Class III Directors        |     | Age |     | Director Since |     | Current Position at                                      
 Immuneering                                              |
| Robert J. Carpenter        |     |  80 |     | May 2009       |     | Director                                                 |
| Benjamin J. Zeskind, Ph.D. |     |  43 |     | February 2008  |     | Co-Founder, President, Chief Executive Officer, Director |

Robert J. Carpenter has served on our Board of Directors since May 2009 and previously served as Chair of the Board through December 2023. Mr. Carpenter also currently serves as the Chairman of Hydra Biosciences LLC, a privately held clinical-stage biopharmaceutical company. From 1992 until 2015, he served as the Chief Executive Officer of Boston Medical Investors, Inc., a venture capital firm. Mr. Carpenter has founded and served in executive management and board roles at numerous biotechnology companies, including Olaris Inc., Integrated Genetics and GelTex Pharmaceuticals, both of which merged with Genzyme Corporation, and VacTex Corp., which was acquired by Aquila Bioph